Breast cancer risk with postmenopausal hormonal treatment

Human Reproduction Update

Volumn 11, Issue 6, 2005, Pages 545-560

  Collins, John A ^a,b,e   Blake, Jennifer M ^c   Crosignani, Pier Giorgio ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MILAN   (Italy)

^e NONE   (Canada)

Author keywords

Breast cancer; Duration of use; Estrogen; Progestin; Recency; Relative risk

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN;

BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MEDLINE; MENOPAUSAL SYNDROME; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MEDLINE; POSTMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 27744584615     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmi028     Document Type: Review

References (75)

1. Ali S and Coombes RC (2000) Estrogen receptor alpha in human breast cancer: Occurrence and significance. J Mammary Gland Biol Neoplasia 5,271-281.
2. Anderson TJ, Battersby S, King RJB, McPherson K and Going JJ (1989) Oral contraceptive use influences resting breast proliferation. Hum Pathol 20,1139-1144.
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner RL, Brzyski RG, Caan BJ et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with a hysterectomy. JAMA 291,1701-1712.
4. Angerer P, Stork S, Kothny W, Schmitt P and von Schacky C (2001) Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial. Arterioscler Thromb Vasc Biol 21,262-268.
5. Antoine C, Liebens F, Carly B, Pastijn A and Rozenberg S (2004) Influence of HRT on prognostic factors for breast cancer: A systematic review after the Women's Health Initiative trial. Hum Reprod 19,741-756.
6. Archer DF, Pickar JH and Bottliglioni F (1994) Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 83,686-692.
7. Beral V and Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362,419-427.
8. Bush TL, Whiteman M and Flaws JA (2001) Hormone replacement therapy and breast cancer: A qualitative review. Obstet Gynecol 98,498-508.
9. Chen C-L, Weiss NS, Newcomb PA, Barlow W and White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287,734-741.
10. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD and Colditz GA (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101,1490-1500.
11. Cherry N, Gilmour K, Hannaford P, Heagarty A, Khan MA, Kitchener HC, McNamee R, Elstein M, Kay C, Seif M et al. (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet 360,2001-2008.
12. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass MLS, Lane DS, Rodabough RJ, Gilligan A, Cyr MG, Thomson CA et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289,3243-3253.
13. The Cochrane Library, Issue 1, (2005). Chichester, UK: John Wiley & Sons, Ltd.
14. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350,1047-1059.
15. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360,187-195.
16. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G et al. (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95,2455-2464.
17. Deeks JJ, Altman DG and Bradburn MJ (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Egger M, Davey Smith G and Altman, DG (eds) Systematic Reviews in Health Care: Meta-Analysis in Context. BMJ Publishing Group, London, pp. 285-312.
18. Delgado RC and Lubian Lopez DM (2001) Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38,147-156.
19. Druckmann R (2003) Progestins and their effects on the breast. Maturitas 46, S59-S69.
20. ESHRE Capri Workshop Group (2004) Hormones and breast cancer. Hum Reprod Update 10,281-293.
21. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM and Olivotto IA (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351,963-970.
22. Gapstur SM, Morrrow M and Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology. JAMA 281,2091-2097.
23. Greendale GA, Reboussin BA, Hogan P, Barnabel VM, Shumaker S, Johnson S, Barrett-Connor E and PEPI Trial Writing Group (1998) Symptom relief and side effects of postmenopausal hormones: Results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 92,982-988.
24. Higgins JPT, Thompson SG, Deeks JJ and Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327,557-560.
25. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu CR, Liu CH and Azen SP (2001) Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135,939-953.
26. Hulley S, Furberg CD, Barrett-Connor E, Cauley J, Grady D, Haskell WL, Knopp R, Lowery M, Satterfield S, Schrott H et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288,58-66.
27. Jernstrom H, Bendahl PO, Lidfeldt J, Nerbrand C, Agardh CD and Samsioe G (2003) A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: The women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control 14,673-680.
28. Kaufman DW, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D and Shapiro S (1984) Noncontraceptive estrogen use and the risk ofbreast cancer. JAMA 252,63-67.
29. Kaufman DW, Palmer JR, de Mouson J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG and Shapiro S (1991) Estrogen replacement therapy and the risk of breast cancer: Results from the case-controlled surveillance study. Am J Epidemiol 134,1375-1385.
30. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DSM, Barlow WE, Cutter GR, Geller BM, Yankaskas B, Taplin SH et al. (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21,4314-4321.
31. Kirsh V and Kreiger N (2002) Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 13,583-590.
32. La Vecchia C (2004) Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. Breast 13,515-518.
33. Lange CA, Richer JK and Horwitz KB (1999) Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13,829-836.
34. LeBlanc ES, Viscoli CM and Henrich JB (1999) Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices. J Womens Health Gend Based Med 8,815-823.
35. Levi F, Te VC, Randimbison L and La Vecchia C (2003) Increase in lobular breast cancer incidence in Switzerland. Int J Cancer 107,164-165.
36. Li CI, Weiss NS, Stanford JL and Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88,2570-2577.
37. Li CI, Anderson BO, Daling JR and Moe RE (2003a) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289,1421-1424.
38. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL and Daling JR (2003b) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289,3254-3263.
39. Lower EE, Blau R, Gazder P and Stahl DL (1999) The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. Breast Cancer Res Treat 58,205-211.
40. Magnusson C, Baron JA, Correia N, Bergstrom R, Adam H-O and Persson I (1999) Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81,339-344.
41. Manjer J, Malina J, Berglund G, Bondeson L, Game JP and Janzon L (2001) Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 92,919-922.
42. Marsden J (2002) Hormone-replacement therapy and breast cancer. Lancet Oncol 3,303-311.
43. Missmer SA, Eliassen AH, Barbieri RL and Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96,1856-1865.
44. Nachtigall LE, Nachtigall RH, Nachtigall RD and Beckman EM (1979) Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54,74-78.
45. Nachtigall MJ, Smilen SW, Nachtigall RD, Nachtigall RH and Nachtigall LE (1992) Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 80,827-830.
46. Nelson HD, Humphrey LL, Nygren P, Teutsch SM and Allan JD (2002) Post-menopausal hormone replacement therapy: Scientific review. JAMA 288,872-881.
47. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC and Stampfer MJ (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11,593-600.
48. Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA and Daling JR (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14,225-233.
49. Olsson HL, Ingvar C and Bladstrom A (2003) Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97,1387-1392.
50. Persson I, Weiderpass E, Bergkvist L, Bergstrom R and Schairer C (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10,253-260.
51. Pike MC and Ross RK (2000) Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer. Steroids 65,659-664.
52. Pike MC, Spicer DV, Dahmoush L and Press MF (1993) Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 15,17-35.
53. Porch JV, Lee IM, Cook NR, Rexrode KM and Buring JE (2002) Estrogen-progestin replacement therapy and breast cancer risk: The Women's Health Study (United States). Cancer Causes Control 13,847-854.
54. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Ferrier EJ and Edwards BK (2003) SEER cancer statistics review, 1975-2000. National Cancer Institute, Bethesda, MD.
55. Ross RK, Paganini-Hill A, Wan PC and Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 92,328-332.
56. Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G and Veronesi U (2002) Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9,266-271.
57. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton LA and Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283,485-491.
58. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW and Thijssen JHH (2003) Classification and pharmacology of progestins. Maturitas 46, S7-S16.
59. Schlesselman JJ (1997) Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 12,1851-1863.
60. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH and Folsom AR (1997) The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history for breast cancer. Ann Intern Med 127,973-980.
61. Singletary SE (2003) Rating the risk factors for breast cancer. Ann Surg 237,474-482.
62. Sitruk-Ware R and Plu-Bureau G (2004) Exogenous progestagens and the human breast. Maturitas 49,58-66.
63. Speirs V, Carder P, Lanes S, Dodwell D, Lansdown MR and Hanby AM (2004) Oestrogen receptor beta: What it means for patients with breast cancer. Lancet Oncol 5,174-181.
64. Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundruo YA, Obel EB, Moller S, Rank F, Ottesen B and Lynge E (2004a) Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 91,644-650.
65. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundruo YA, Obel EB and Ottesen B (2004b) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109,721-727.
66. Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA and Hole DJ (2000) Effect of hormone replacement therapy on the pathological stage of breast cancer: Population based, cross-sectional study. BMJ 320,348-349.
67. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR and Jones DR (2000) Empirical assessment of effect of publication bias on meta-analyses. BMJ 320,1574-1577.
68. The Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94,606-616.
69. Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overad K, Ewertz M and Mellemkjaer L (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: A prospective Danish cohort study. Cancer 100,2328-2337.
70. Verkooijen HM, Fioretta G, Vlastros G, Morabia A, Schubert H, Sappino AP, Pelte MF, Schafer P, Kurtz J and Bouchardy C (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104,778-781.
71. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S and Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345,1243-1249.
72. Warren MP (2004) A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 190,1141-1167.
73. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA et al. (2002) Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 100,1148-1158.
74. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 288,321-333.
75. Zeleniuch-Jacquotte A, Toniolo P, Levitz M, Koenig KL, Banerjee S, Strax P and Pasternack BS (1995) Endogenous estrogens and risk of breast cancer by estrogen receptor status: A prospective study in postmenopausal women. Cancer Epidemiol Biomarkers Prev 4,857-860.